Newron and EA Pharma Announce License Agreement for Evenamide in Japan and Other Asian Territories

Newron and EA Pharma Announce License Agreement for Evenamide in Japan and Other Asian Territories

12/13/24, 12:07 PM
Money
€117 million
Industry
biopharma
therapeutics
pharmaceutical
biotechnology
health care
Type
agreement
Newron Pharmaceuticals S.p.A. and EA Pharma Co., Ltd. have entered into a license agreement to develop, manufacture, and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, in Japan and other designated Asian territories. The agreement includes an upfront payment of €44 million and financial contributions to Newron’s upcoming Phase III study, with total potential payments of up to €117 million

Company Info

Company
Newron Pharmaceuticals S.p.A. & EA Pharma Ltd
Additional Info
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. EA Pharma Co., Ltd. is a subsidiary of Eisai Co., Ltd. focused on pharmaceutical development.